Key result
Gene therapy-delivered IL-13 (AxCAIL-13) decreased the production of proinflammatory cytokines, including IL-1beta by 85% and TNF-alpha by up to 82%, in rheumatoid arthritis synovial tissue explants.
Why the study?
Does gene therapy-delivered IL-13 reduce the production of proinflammatory mediators in rheumatoid arthritis synovial tissue explants?
Population
Rheumatoid arthritis (RA) synovial tissue (ST) explants and RA synovial fibroblasts
Comparison
Adenoviral vectors encoding the genes for human… vs Adenoviral vectors encoding bacterial…
Design
Preclinical
Follow-up
Up to 72 hours
Authors
Loading...
Hypothesis-generating for IL-13 gene therapy in RA; leaves open clinical translation pending human studies.
Does gene therapy-delivered IL-13 reduce the production of proinflammatory mediators in rheumatoid arthritis synovial tissue explants?
Gene therapy-delivered IL-13 significantly reduces the secretion of multiple proinflammatory cytokines and PGE2 in rheumatoid arthritis synovial tissue explants.
Woods et al. (2000) studied Rheumatoid arthritis. Adenoviral vectors encoding human IL-13 (AxCAIL-13) vs. Adenoviral vectors encoding bacterial beta-galactosidase was evaluated on Production of key proinflammatory mediators in RA synovial tissue explants. Gene therapy-delivered IL-13 (AxCAIL-13) decreased the production of proinflammatory cytokines, including IL-1beta by 85% and TNF-alpha by up to 82%, in rheumatoid arthritis synovial tissue explants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: